Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Issues Final Guidance on Best Practices for Convening a GRAS PanelCFSAN Constituent Updates FDA Issues Final Guidance on Best Practices for Convening a GRAS Panel
  
  	
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

December 20, 2022

Today, the U.S. Food and Drug Administration (FDA) issued a final guidance titled Best Practices for Convening a GRAS Panel. Although in most cases general recognition of safety can be supported without convening a GRAS panel, this guidance provides information to those assembling a panel of experts (“GRAS panel”) to evaluate whether there is general acceptance among the scientific community that the publicly available scientific data and information demonstrate that a substance is safe under the conditions of its intended use in human or animal food.

For a substance to be generally recognized as safe (GRAS) under the conditions of its intended use, the publicly available data and information must show it meets the safety standard for a food additive. Additionally, there must be common knowledge throughout the scientific community knowledgeable about the safety of substances directly or indirectly added to food that there is reasonable certainty that the substance is not harmful under the intended conditions of use.

Under the GRAS provision established by the Federal Food, Drug, and Cosmetic Act, the use of a substance that is GRAS does not require pre-market approval by the FDA as a food additive. In most cases, a well-supported GRAS conclusion will not need evaluation by a GRAS panel as evidence of general acceptance. For example, peer-reviewed primary safety studies or secondary reviews of primary literature may provide evidence of general acceptance. However, the final guidance includes information on the value of a GRAS panel in providing evidence, in specific circumstances, to support the “general acceptance” aspect of the eligibility criteria for GRAS status through scientific procedures.

In finalizing this guidance, the FDA considered comments on the draft guidance issued in November 2017. The final guidance clarifies the difference between a GRAS panel and an FDA advisory committee, and highlights best practices to help those interested in convening a GRAS panel, including:

Identifying GRAS panel members who have appropriate and balanced expertise.
	Steps to reduce the risk of bias, or the appearance of bias, that may affect the credibility of the GRAS panel’s report, including assessing potential GRAS panel members for conflict of interest and the appearance of conflict of interest.
	Limiting the data and information provided to a GRAS panel to publicly available information.Clarifying best practices for convening a GRAS panel helps promote a consistent, science-based approach to evaluating the safety of substances added to human or animal food.

The public may submit electronic or written comments related to this final guidance at any time. Public comments can be submitted electronically to Regulations.gov with the docket number: FDA-2017-D-0085. Written comments should be identified with the docket number: FDA-2017-D-0085 and the title of the guidance document and submitted to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm.1061, Rockville, MD 20852.

For questions about the final guidance as it relates to substances used in human food, contact the Center for Food Safety and Applied Nutrition (CFSAN) at 240-402-1200.

For questions about the final guidance as it relates to substances used in animal food, contact the Center for Veterinary Medicine (CVM) at 240-402-7002.

**For More Information:**

Federal Register Notice
	Final Guidance for Industry: Best Practices for Convening a GRAS Panel
	Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food
	GRAS Final Rule
	Frequently Asked Questions about GRAS

                                                                                  Content current as of:
      12/20/2022
              
              
Regulated Product(s)
		 Food & BeveragesCFSAN Constituent Updates
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop